JP2006519028A5 - - Google Patents

Download PDF

Info

Publication number
JP2006519028A5
JP2006519028A5 JP2006508841A JP2006508841A JP2006519028A5 JP 2006519028 A5 JP2006519028 A5 JP 2006519028A5 JP 2006508841 A JP2006508841 A JP 2006508841A JP 2006508841 A JP2006508841 A JP 2006508841A JP 2006519028 A5 JP2006519028 A5 JP 2006519028A5
Authority
JP
Japan
Prior art keywords
influenza virus
composition
influenza
egg
live
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006508841A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006519028A (ja
JP4617300B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/005697 external-priority patent/WO2005014862A1/en
Publication of JP2006519028A publication Critical patent/JP2006519028A/ja
Publication of JP2006519028A5 publication Critical patent/JP2006519028A5/ja
Application granted granted Critical
Publication of JP4617300B2 publication Critical patent/JP4617300B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006508841A 2003-02-25 2004-02-25 インフルエンザワクチン組成物を生成する方法 Expired - Fee Related JP4617300B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45018103P 2003-02-25 2003-02-25
PCT/US2004/005697 WO2005014862A1 (en) 2003-02-25 2004-02-25 Methods of producing inflenza vaccine compositions

Publications (3)

Publication Number Publication Date
JP2006519028A JP2006519028A (ja) 2006-08-24
JP2006519028A5 true JP2006519028A5 (https=) 2007-04-12
JP4617300B2 JP4617300B2 (ja) 2011-01-19

Family

ID=34135009

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006508841A Expired - Fee Related JP4617300B2 (ja) 2003-02-25 2004-02-25 インフルエンザワクチン組成物を生成する方法

Country Status (8)

Country Link
US (5) US7262045B2 (https=)
EP (2) EP1597400B8 (https=)
JP (1) JP4617300B2 (https=)
KR (4) KR101190932B1 (https=)
CN (2) CN100582244C (https=)
AU (2) AU2004263813B8 (https=)
CA (2) CA2807534A1 (https=)
WO (1) WO2005014862A1 (https=)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
ES2526191T3 (es) 2002-04-26 2015-01-08 Medimmune, Llc Método para producir virus influenza B infeccioso en cultivo celular
CN1788089A (zh) * 2002-07-03 2006-06-14 巴斯福股份公司 用于提高泛酸产量的微生物和方法
US7262045B2 (en) 2003-02-25 2007-08-28 Medimmune Vaccines, Inc. Methods of producing influenza vaccine compositions
US20060110406A1 (en) 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
ATE469972T1 (de) 2003-12-23 2010-06-15 Medimmune Llc Multiplasmid-system zur erzeugung des grippevirus
EP2821135A1 (en) * 2004-02-05 2015-01-07 EMD Millipore Corporation Porous adsorptive or chromatographic media
JP5147405B2 (ja) * 2004-10-06 2013-02-20 メディミューン，エルエルシー 冷蔵温度安定型インフルエンザワクチン組成物
ES2536745T3 (es) 2004-12-08 2015-05-28 Medimmune, Llc Métodos de producción de composiciones de vacuna contra la gripe
ATE547511T1 (de) 2004-12-23 2012-03-15 Medimmune Llc Nichttumorbildende mdck-zellinie zur vermehrung von viren
EP2441471B1 (en) 2005-03-08 2014-10-08 MedImmune, LLC Reassortant influenza viruses
EP3088893B1 (en) * 2005-04-13 2018-02-14 Merial, Inc. Assay for monitoring porcine circovirus production
CN101189030A (zh) * 2005-06-02 2008-05-28 阿尔扎公司 透皮递送器械的最终消毒方法
US7790434B2 (en) * 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
RU2008101367A (ru) 2005-06-21 2009-08-10 Медиммун, Ллк (Us) Способы и композиции для экспрессии отрицательной смысловой вирусной рнк в собачьих клетках
WO2007019232A2 (en) 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
GB0613977D0 (en) * 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
US7534596B2 (en) * 2006-02-10 2009-05-19 Solohill Engineering, Inc. Method and device for producing vaccine
PT2016194E (pt) 2006-04-19 2015-07-20 Medimmune Llc Métodos e composições para expressar arn viral de polaridade negativa em células caninas
GB0614460D0 (en) * 2006-07-20 2006-08-30 Novartis Ag Vaccines
WO2008105931A2 (en) 2006-09-15 2008-09-04 Medimmune Vaccines, Inc. Mdck cell lines supporting viral growth to high titers and bioreactor process using the same
KR20090088944A (ko) * 2006-12-15 2009-08-20 쉐링-프라우 리미티드 배양물 속에서 인플루엔자 바이러스를 복제하는 방법
AR065640A1 (es) * 2007-03-09 2009-06-17 Otsuka Pharma Co Ltd Preparado liofilizado que contiene una vacuna contra la influenza y metodo para producir la misma
CA2690196A1 (en) 2007-06-18 2008-12-24 Medimmune, Llc Influenza b viruses having alterations in the hemaglutinin polypeptide
US9433922B2 (en) * 2007-08-14 2016-09-06 Emd Millipore Corporation Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same
EP2217064A4 (en) * 2007-11-12 2012-10-03 Univ Pennsylvania NEW VACCINES FOR FIGHT AGAINST SEVERAL SUBTYPES OF INFLUENZA VIRUSES
US20090130738A1 (en) * 2007-11-19 2009-05-21 Mikhail Kozlov Media for membrane ion exchange chromatography
EP2072058A1 (en) * 2007-12-21 2009-06-24 Avir Green Hills Biotechnology Research Development Trade Ag Modified influenza virus
JP2011184299A (ja) * 2008-07-02 2011-09-22 Asahi Kasei Medical Co Ltd モノクローナル抗体を含む製剤の製造方法
CN102215865B (zh) 2008-09-24 2013-10-30 米迪缪尼有限公司 病毒纯化方法
RU2547587C2 (ru) 2008-09-24 2015-04-10 Медиммун, Ллк Способы культивирования клеток, размножения и очистки вирусов
US8815252B2 (en) * 2008-11-25 2014-08-26 Baxter Healthcare Sa Method for production of pH stable enveloped viruses
JP5686741B2 (ja) 2008-12-16 2015-03-18 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ インフルエンザワクチンの生成
CN101450209B (zh) * 2008-12-31 2012-01-25 中国人民解放军军事医学科学院微生物流行病研究所 透皮免疫流感多价疫苗的制备及其方法
RU2424762C2 (ru) * 2009-05-06 2011-07-27 Валерий Денисович Белокрылов Способ и автоматизированное устройство (два варианта) для диагностики заболеваний, вызванных вирусом a/h1n1 и его мутациями
WO2010144797A2 (en) 2009-06-12 2010-12-16 Vaccine Technologies, Incorporated Influenza vaccines with enhanced immunogenicity and uses thereof
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
AU2010270722B2 (en) 2009-07-06 2015-06-04 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
US20120077249A1 (en) * 2010-04-20 2012-03-29 Millipore Corporation Separation Of Virus And/Or Protein From Nucleic Acids By Primary Amines
MX342138B (es) 2010-07-06 2016-09-14 Variation Biotechnologies Inc Composiciones y metodos para el tratamiento de influenza.
US8606750B2 (en) * 2010-11-12 2013-12-10 Life Technologies Corporation Systems and methods for laboratory assay validation or verification
CA2862871C (en) 2011-01-13 2020-09-22 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
CA2862864C (en) 2011-01-13 2018-12-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP2694645A1 (en) 2011-04-08 2014-02-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for increasing the replication capacity of an influenza virus in cultured cells
EP2710381A2 (en) 2011-05-16 2014-03-26 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods for screening substances capable of modulating the replication of an influenza virus
CA2841604C (en) * 2011-07-20 2020-01-21 Abbott Biologicals B.V. Process for producing viral antigen and vaccines
US20140328876A1 (en) 2011-11-18 2014-11-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
WO2013092985A1 (en) * 2011-12-23 2013-06-27 Novartis Ag Stable compositions for immunising against staphylococcus aureus
US20140356399A1 (en) 2012-01-12 2014-12-04 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
US20150079077A1 (en) 2012-01-27 2015-03-19 Variation Biotechnologies, Inc. Methods and compositions for therapeutic agents
US20130309700A1 (en) * 2012-05-21 2013-11-21 Celsis International Limited Methods, devices, and systems of detecting microorganisms
US9932620B2 (en) 2012-05-21 2018-04-03 Celsis Ltd. Methods, devices, and systems of detecting microorganisms
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
KR20140112255A (ko) 2013-03-13 2014-09-23 고려대학교 산학협력단 바이러스 생산능이 증가된 세포주 및 그 제조방법
EP2975119B1 (en) 2013-03-13 2020-03-11 ImmunoMax Co., Ltd. Cell strain having increased virus production ability and production method therefor
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
WO2015017673A1 (en) * 2013-08-01 2015-02-05 Medimmune, Llc Methods for producing influenza vaccine compositions
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
US9579374B2 (en) 2013-12-04 2017-02-28 The Johns Hopkins University Method for rapidly designing pharmaceutical preparations for preventing viral infection
AR099470A1 (es) 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
TWI670085B (zh) * 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
US10426828B2 (en) * 2014-04-03 2019-10-01 Biondvax Pharmaceuticals Ltd. Compositions of multimeric-multiepitope influenza polypeptides and their production
JP6708636B2 (ja) 2014-06-18 2020-06-10 イミュノマックス カンパニー リミテッドＩｍｍｕｎｏｍａｘ Ｃｏ．， Ｌｔｄ． Ｂｓｔ２遺伝子の機能が喪失された細胞株を利用したウィルス感染促進及び産生増進方法
AU2015357225B2 (en) 2014-12-01 2020-04-09 Transgene Sa Stable liquid vaccinia virus formulations
ES3011733T3 (en) 2015-02-13 2025-04-08 Transgene Immunotherapeutic vaccine and antibody combination therapy
CN104984357B (zh) * 2015-06-02 2018-01-30 长春百克生物科技股份公司 不含明胶的疫苗保护剂组合物及流感减毒活疫苗
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
WO2017090769A1 (ja) * 2015-11-27 2017-06-01 日東電工株式会社 インフルエンザワクチン乾燥製剤、及び、インフルエンザワクチン乾燥製剤の製造方法
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
JP7034949B2 (ja) 2016-05-25 2022-03-14 テルモ ビーシーティー、インコーポレーテッド 細胞の増殖
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
CN117247899A (zh) 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增
CN110603058A (zh) 2017-05-15 2019-12-20 扬森疫苗与预防公司 含有病毒的稳定组合物
KR102658198B1 (ko) 2017-05-15 2024-04-16 얀센 백신스 앤드 프리벤션 비.브이. 안정한 바이러스 함유 조성물
JP2021516957A (ja) 2018-03-07 2021-07-15 トランジェーヌＴｒａｎｓｇｅｎｅ パラポックスウイルスベクター
JP7625521B2 (ja) 2018-12-28 2025-02-03 トランスジーン ｍ２欠陥ポックスウイルス
WO2020136232A1 (en) 2018-12-28 2020-07-02 Transgene Sa Immunosuppressive m2 protein
JP7660514B2 (ja) * 2019-02-15 2025-04-11 セラム インスティチュート オブ インディア プライベイト リミテッド 弱毒生インフルエンザワクチン組成物及びその調製プロセス
US20230114464A1 (en) * 2020-03-12 2023-04-13 Bavarian Nordic A/S Conditions Improving Poxvirus Stability
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager
KR20260001978A (ko) 2024-06-28 2026-01-06 주식회사 엔에프방재 화재 방재용 방패

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB660109A (en) * 1946-10-01 1951-10-31 American Cyanamid Co Improvements in or relating to the treatment of allantoic fluid containing a propagated virus together with non-viral proteins to obtain the virus in purified and viable from for use in a vaccine
US4158054A (en) * 1973-10-18 1979-06-12 Duncan Flockhart & Co. Ltd. Preparation of virus sub-unit vaccines
US3874999A (en) * 1973-10-31 1975-04-01 American Cyanamid Co Process for the purification of virus vaccine
US4000257A (en) * 1975-12-22 1976-12-28 American Cyanamid Company Process for the purification of influenza virus vaccine
US4057626A (en) 1976-10-08 1977-11-08 Richardson-Merrell Inc. Process for detoxifying influenza B virus
US4338296A (en) * 1979-10-16 1982-07-06 Smithkline-Rit Influenza virus and process of producing a vaccine therefrom
JPS57114527A (en) * 1979-10-29 1982-07-16 Merck & Co Inc Vaccine stabilizer
US4338335A (en) * 1980-02-05 1982-07-06 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
US4337242A (en) * 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
US4512972A (en) * 1980-06-30 1985-04-23 Kureha Chemical Industry Co., Ltd. Nasal preparation and processes for their production
FR2505657A1 (fr) 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
US4512285A (en) * 1983-12-27 1985-04-23 Gof Manufacturing Company, Inc. Apparatus and method for egg turning during incubation
GB8914968D0 (en) 1989-06-29 1989-08-23 Connaught Lab Production of virus and purification of viral envelope proteins for vaccine use
CA2065023A1 (en) * 1989-08-15 1991-02-16 Brent Dorval Stabilized vaccine compositions
CA2075521C (en) 1992-05-05 1995-11-28 Kuniaki Koyama Stabilized live vaccine
US7344722B1 (en) * 1993-06-29 2008-03-18 The Regents Of The University Of Michigan Cold-adapted influenza virus
US5824536A (en) 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
US6146873A (en) 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
EP0865296B1 (en) 1995-10-20 2002-02-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Influenza vaccine
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
TW570803B (en) * 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6177082B1 (en) * 1998-08-13 2001-01-23 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
CA2355270A1 (en) 1998-12-17 2000-06-22 Aventis Pasteur Limited Multivalent immunogenic composition containing rsv subunit composition and influenza virus preparation
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
IL149459A0 (en) * 1999-11-12 2002-11-10 Fibrogen Inc Recombinant gelatins
CN1147316C (zh) * 2000-03-16 2004-04-28 辽宁天成生物制药研究所 流感病毒静水压技术灭活工艺制备疫苗的方法
MXPA02010642A (es) 2000-04-28 2004-05-17 St Jude Children S Res Hospital Sistema de transfeccion de adn para la generacion de virus de influenza infeccioso.
BRPI0002694C1 (pt) 2000-06-19 2021-05-25 Fund Butantan processo de obtenção de vacina contra raiva em células vero, para uso humano
US7494659B2 (en) 2000-09-25 2009-02-24 Polymun Scientific Immunbiologische Forschung Gmbh Live attenuated influenza vaccine
ATE503493T1 (de) 2001-02-23 2011-04-15 Glaxosmithkline Biolog Sa Influenza vakzinzusammensetzungen zur intradermaler verabreichung
TWI228420B (en) 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
WO2004030608A2 (en) * 2001-06-05 2004-04-15 The Regents Of The University Of Michigan Nanoemulsion vaccines
US7195905B2 (en) 2001-12-10 2007-03-27 Baxter Healthcare S.A. Enveloped virus vaccine and method for production
US7135180B2 (en) * 2002-04-11 2006-11-14 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
CA2484052C (en) * 2002-04-11 2011-06-14 Medimmune Vaccines, Inc. Preservation of bioactive materials by spray drying
ES2526191T3 (es) 2002-04-26 2015-01-08 Medimmune, Llc Método para producir virus influenza B infeccioso en cultivo celular
KR20050088175A (ko) 2002-12-17 2005-09-02 메드이뮨 백신즈 인코포레이티드 생물활성 물질의 고압 분무 건조
US7262045B2 (en) 2003-02-25 2007-08-28 Medimmune Vaccines, Inc. Methods of producing influenza vaccine compositions
US20060110406A1 (en) 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
ATE469972T1 (de) 2003-12-23 2010-06-15 Medimmune Llc Multiplasmid-system zur erzeugung des grippevirus
EP2995678A1 (en) 2004-05-24 2016-03-16 MedImmune, LLC Multi plasmid system for the production of attenuated influenza b virus
JP5147405B2 (ja) 2004-10-06 2013-02-20 メディミューン，エルエルシー 冷蔵温度安定型インフルエンザワクチン組成物

Similar Documents

Publication Publication Date Title
JP2006519028A5 (https=)
WO2005014862B1 (en) Methods of producing inflenza vaccine compositions
Kumar et al. Virological and immunological outcomes of coinfections
Almansour Mumps vaccines: current challenges and future prospects
Fu et al. Emergence of a new GII. 17 norovirus variant in patients with acute gastroenteritis in Jiangsu, China, September 2014 to March 2015
Chan et al. Tropism and replication of Middle East respiratory syndrome coronavirus from dromedary camels in the human respiratory tract: an in-vitro and ex-vivo study
Bello et al. Diagnostic and vaccination approaches for Newcastle disease virus in poultry: The current and emerging perspectives
Hanley et al. Paired charge-to-alanine mutagenesis of dengue virus type 4 NS5 generates mutants with temperature-sensitive, host range, and mouse attenuation phenotypes
Hannoun The evolving history of influenza viruses and influenza vaccines
Schmidt et al. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone
Colas de la Noue et al. Absolute humidity influences the seasonal persistence and infectivity of human norovirus
Hosseini et al. Molecular characterization and phylogenetic study of Newcastle disease viruses isolated in Iran, 2010–2012
Wen et al. Molecular basis for the thermostability of Newcastle disease virus
Yadav et al. Characterization of novel reoviruses wad medani virus (orbivirus) and kundal virus (coltivirus) collected from hyalomma anatolicum ticks in india during surveillance for crimean congo hemorrhagic fever
CN105517568B (zh) 防止病毒组分聚集的方法
Ábrego et al. Genetic variability of human respiratory syncytial virus group B in Panama reveals a novel genotype BA14
Takeuchi et al. Wild-type measles virus with the hemagglutinin protein of the Edmonston vaccine strain retains wild-type tropism in macaques
Emara et al. Mutation of mapped TIA-1/TIAR binding sites in the 3′ terminal stem-loop of West Nile virus minus-strand RNA in an infectious clone negatively affects genomic RNA amplification
Takeuchi et al. Recombinant wild-type and Edmonston strain measles viruses bearing heterologous H proteins: role of H protein in cell fusion and host cell specificity
Silva et al. Recent advances and current challenges in process intensification of cell culture‐based influenza virus vaccine manufacturing
Yang et al. Case report for human infection with a highly pathogenic avian influenza A (H5N6) virus in Beijing, China 2019
Sreenivasan et al. Influenza C and D viruses demonstrated a differential respiratory tissue tropism in a comparative pathogenesis study in guinea pigs
Bartlett et al. Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys
Escoffier et al. Infection of chicken embryonic fibroblasts by measles virus: adaptation at the virus entry level
Joseph et al. Adaptive evolution during the establishment of European avian‐like H 1 N 1 influenza A virus in swine